Tvardi Therapeutics
Business Services · Texas, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3 Sugar Creek Center Blvd Ste 525, Sugar...Phone Number
(713) 489-8654Website
www.tvarditherapeutics.comRevenue
-Stock Symbol
TVRDIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
2
2
1
1
1
About Tvardi Therapeutics
Tvardi Therapeutics, Inc. is a clinical-stage biotechnology company based in Houston, Texas, USA, focused on developing a new class of breakthrough medicines for fibrosis-driven diseases. Founded in 2017, the company is led by a team of experienced entrepreneurs, innovative scientists, and dedicated physicians committed to advancing novel therapies that address significant unmet medical needs. Operating in the Biotechnology / Pharmaceutical Research industry, Tvardi Therapeutics leverages cutting-edge science and clinical expertise to discover and develop therapies that inhibit key disease pathways, aiming to improve patient outcomes and reduce the societal and economic impact of fibrosis-related conditions. The company conducts clinical trials to evaluate the safety and efficacy of its therapeutics and is dedicated to translating scientific innovation into meaningful treatments for patients worldwide.Explore more
Tvardi Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Tvardi Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Tvardi Therapeutics has new funding data
Tvardi Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Tvardi Therapeutics is spiking on competitors!
Product Launch: Get notified when Tvardi Therapeutics launches new products
Check if Tvardi Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Tvardi Therapeutics
Click to see if Tvardi Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Tvardi Therapeutics recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Tvardi Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Tvardi Therapeutics
Compare insights from companies similar to Tvardi Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Tvardi Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Tvardi Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Tvardi Therapeutics.
Tvardi Therapeutics financials insights
Gather financial insights about Tvardi Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$9M
2020
Grant
$5M
2021
Series B
$74M
Tvardi Therapeutics Tech Stack
A closer look at the technologies used by Tvardi Therapeutics
See more technologies
Most Recent Scoops
Project
noted that the HRCT fibrosis scores and IL-6 blood level measurements from the REVERT-IPF post hoc analysis are considered fully valid objective measures, as the pre- and post-treatment scans were read independently and in a blinded fashion, and the observed decrease in fibrosis a finding not previously demonstrated in any prior IPF trial to the company's knowledge, whether over 12 or 52 weeks is consistent with preclinical data showing therapeutic reversal of fibrosis in animal models.
Medical Research
Project
reported that a post hoc analysis of patients who completed the REVERT-IPF trial demonstrated a 7% placebo-adjusted reduction in fibrosis, as measured via pre- and post-treatment HRCTs read independently and in a blinded fashion, representing what the company believes to be the first trial to show an actual decrease in fibrosis over a 12-week period rather than merely preventing an increase.
Medical Research
Project
reported that patients who completed the 400 mg or 800 mg arms of its Phase II IPF trial demonstrated an actual decrease in fibrosis, with a placebo-adjusted 7% reduction observed over 12 weeks the first time such a reversal has been shown in a trial of this duration, as assessed by independently blinded and centralized measurement.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Tvardi Therapeutics has demonstrated in IND-enabling studies that TTI-109 passes through the gastrointestinal tract without exposing active drug to GI tissue, converting to its active form TTI-101 in the bloodstream via phosphatases, with over 95% conversion observed within 2 hours at the highest dose in primate studies, alongside no observed toxicity and strong GLP safety margins.
Medical Research, Pharmaceuticals
Project
Medical Research, Pharmaceuticals
Tvardi Therapeutics News & Media
Tvardi Therapeutics to Participate in Upcoming Investor Events
HOUSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that management will participate in the following upcoming investor events:Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update
Topline results from healthy volunteer study and clinical development strategy for next-generation STAT3 inhibitor, TTI-109, anticipated in JuneTvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium
HOUSTON, April 02, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that management will participate in one-on-one investor meetings at the upcoming Raymond James Biotech Innovation Symposium in New York City, on April 14th, 2026.Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update
Results from healthy volunteer study of next-generation STAT3 inhibitor, TTI-109, on track for Q2 2026
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Tvardi Therapeutics
Sign Up For FreeTo access detailed company insights
Tvardi Therapeutics, Inc. is a clinical-stage biotechnology company based in Houston, Texas, USA, focused on developing a new class of breakthrough medicines for fibrosis-driven diseases. Founded in 2017, the company is led by a team of experienced entrepreneurs, innovative scientists, and dedicated physicians committed to advancing novel therapies... Read More
